International Journal of Pharmaceutical research and Applications
Volume 11, Issue 1, Jan - Feb 2026, pp:112-117 www.ijprajournal.com ISSN: 2456-4494

Liver Fibrosis: An Integrative Review of Molecular Pathogenesis and Treatment Approaches

Rajkeerti Niwasan[1], Bhanu Pratap[1], Neelesh[1], Priyanka Prajapati[2*]
[1]Student, Department of Pharmacology, Krishna Institute of Pharmacy and Sciences, Kanpur (209217) UP, India.
[2]Associate Professor, Department of Pharmacology, Krishna Institute of Pharmacy andSciences, Kanpur (209217), UP, India.
*Corresponding author

Date of Submission: 03-01-2026 Date of acceptance: 14-01-2026

Abstract: A surplus of extracellular matrix (ECM) proteins, mostly collagen, characterizes the pathological state known as liver fibrosis, which alters the hepatic architecture and compromises liver function. Chronic liver damage caused by hepatitis B and C virus infection, alcohol abuse, non-alcoholic fatty liver disease (NAFLD), and autoimmune illnesses initiates a complex cascade of cellular mechanisms. Tissue remodeling, oxidative stress, inflammation, and hepatic stellate cell (HSC) activation are all regulated by a variety of molecular signaling pathways. This comprehensive analysis highlights the mechanisms, relationships, and possible therapeutic applications of the major molecular signaling pathways implicated in hepatic fibrogenesis.

Keywords: Fatty liver, liver fibrosis, Inflammation, Oxidative stress, hepatic cellular, extra cellular matrix.

I. Introduction:

The liver's wound-healing reaction to a damage is known as hepatic fibrosis.Persistent injury leads to chronic inflammation and progressive fibrotic remodeling, which may culminate in cirrhosis and hepatocellular carcinoma (HCC)[1,2].



Figure 1: Epidemiology of Liver Fibrosis

The stimulation of HSCs, which develop into proliferative, fibrogenic myofibroblasts, is the fundamental cause of fibrosis[3]. Molecular signaling cascades are key regulators of this process[4]. Understanding these pathways can pave the way for identifying biomarkers and therapeutic targets[5].



Figure 2: Molecular signaling involved in Liver Fibrosis

2. Transforming Growth Factor-β (TGF-β) PathwayTGF-β1 is a major regulator of fibrogenesis. Upon binding to type I and type II TGF-β receptors, phosphorylated SMAD2/3 forms a complex with SMAD4 and enters the nucleus. By increasing the transcription of ECM genes including COL1A1 and fibronectin, this complex slows ECM breakdown in addition to upregulating matrix metalloproteinases (MMPs) and downregulating tissue inhibitors of metalloproteinases (TIMPs)[3]. Targeting TGF-β signaling is a key strategy in antifibrotic therapy[3,4].

3. Platelet-Derived Growth Factor (PDGF) Signaling PDGF, especially PDGF-BB, is a potent mitogen for HSCs. Binding to PDGF receptor β activates downstream PI3K/Akt, ERK/MAPK, and JAK/STAT pathways[6]. These signals induce HSC proliferation, survival, chemotaxis, and secretion of ECM components. Elevated PDGF signaling is consistently found in fibrotic liver tissues, and its blockade has shown antifibrotic effects in preclinical studies[5].

4. Wnt/β-Catenin Signaling Liver regeneration and fibrogenesis are both influenced by the Wnt/β-catenin pathway. By binding to Frizzled receptors and LRP5/6 co-receptors, Wnt ligands stabilize β-catenin, which enters the nucleus and initiates the transcription of target genes involved in extracellular matrix formation and cell division[7]. Dysregulated Wnt signaling sustains fibrotic progression and HSC activation. Researchers are investigating the use of inhibitors of this pathway in fibrosis treatment[7,8].

5. Hedgehog (Hh) Signaling TheHh pathway is normally silent in adult liver but becomes reactivated during injury. Smoothened (SMO) inhibition is removed and GLI transcription factors are activated when Hh ligands (Shh, Ihh) attach to the Patched (PTCH) receptor. This signaling enhances HSC activation, fibrogenesis, and angiogenesis, and is linked with the expansion of liver progenitor cells in fibrosis. Hh pathway inhibitors have demonstrated therapeutic potential in experimental models[9].

6. The Pathway of Nuclear Factor-kappa B (NF-κB) NF-κBis a significant inflammatory mediator in liver fibrosis. When TNF-α and IL-1β, two cytokines, activate NF-κB, it moves to the nucleus and triggers the production of pro-inflammatory genes. This communication indirectly promotes

International Journal of Pharmaceutical research and Applications
Volume 11, Issue 1, Jan - Feb 2026, pp:112-117 www.ijprajournal.com ISSN: 2456-4494

HSC activation, maintains the inflammatory environment, and improves immune cell recruitment[10]. Anti-inflammatory agents modulating NF-κB activity are being evaluated for antifibrotic efficacy[11].

7. Janus Kinase/Activator of Transcription and Signal Transducer (JAK/STAT) Cytokine binding to receptors activates pathway JAKs, which phosphorylates STATs.Activated STATs dimerize and regulate transcription of genes involved in inflammation and fibrosis. STAT3 is particularly important in HSC proliferation and anti-apoptotic signaling. JAK inhibitors like ruxolitinib are undergoing evaluation in liver disease contexts[6,12].

8. Oxidative Stress and Nrf2 Pathway Chronic liver injury induces oxidative stress via ROS production from damaged mitochondria and activated immune cells. ROS activates HSCs and contributes to ECM accumulation[13,14]. The antioxidant response is controlled by the Nrf2-Keap1-ARE pathway[15]. The expression of antioxidant and detoxifying enzymes is induced by Nrf2 activation.(e.g., HO-1, NQO1), counteracting ROS-mediated damage. Pharmacological Nrf2 activators are being considered for clinical trials[16,17].

9. Hippo-YAP/TAZ Pathway The Hippo pathway controls cell division and organ growth. Inactive YAP/TAZ translocates to the nucleus, where it stimulates the epithelial-mesenchymal transition (EMT) in hepatocytes and pro-fibrotic gene expression in HSCs[18,19]. Aberrant Hippo signaling is associated with fibrogenesis and carcinogenesis, making it an attractive therapeutic target[20,21].

10. Toll-Like Receptor (TLR) Signaling TLRs, especially TLR4, sense molecular patterns linked to pathogens and damage (PAMPs/DAMPs). MyD88-dependent signaling is facilitated by TLR4 activation, which ultimately results in NF-κB activation and cytokine release. TLR signaling increases HSC activation and inflammation[22,23]. In animal models, TLR4 inhibitors have demonstrated potential in lowering fibrosis.

11. Crosstalk Between Signaling Pathways Signaling pathways involved in liver fibrosis do not function in isolation. There is significant crosstalk—for instance:

- TGF-β enhances Wnt and NF-κB signaling[24].
- Oxidative stress potentiates PDGF and TGF-β signaling[3].
- STAT and Hh pathways interact with inflammatory circuits. A systems biology approach is essential to develop effective, multitargeted therapies[25].



Figure: A central liver schematic showing: Activation of HSCs and Kupffer cells[26], Pathway arrows from each signaling axis (e.g., TGF-β, PDGF) converging on ECM production[3,27], Color-coded interactions (e.g., red for pro-fibrotic, green for protective mechanisms)[26,28].

International Journal of Pharmaceutical research and Applications
Volume 11, Issue 1, Jan - Feb 2026, pp:112-117 www.ijprajournal.com ISSN: 2456-4494

Table 1: Therapeutic Interventions in Clinical Trials for Liver Fibrosis

Therapeutic Agent	Target / Mechanism	Clinical Status	Notes
Galunisertib	TGF-β receptor I (ALK5) inhibitor	Phase II (completed)	Reduces fibrogenic SMAD signaling
Fresolimumab	Neutralizing antibody against TGF-β	Phase I/II	Broad TGF-β isoform blockade
Cenicriviroc (CVC)	CCR2/CCR5 dual antagonist	Phase IIb (completed)	Targets inflammation and fibrosis
Obeticholic acid (OCA)	FXR agonist	Phase III (REGENERATE)	Modulates bile acid signaling and inflammation
Selonsertib	ASK1 inhibitor	Phase III (halted)	Inhibits apoptosis and inflammation; failed to meet endpoints
Elafibranor	PPARα/δ agonist	Phase III (RESOLVE-IT)	Targets lipid metabolism and inflammation
Lanifibranor	Pan-PPAR agonist	Phase IIb	Improved fibrosis score in NASH patients
NGM282 (Aldafermin)	FGF19 analogue	Phase IIb	Reduces bile acid synthesis; anti-inflammatory
RO7062931	GalNAc-conjugated siRNA targeting HSCs (TGF-β)	Phase I	RNAi approach for targeted delivery
BMS-986263	Lipid nanoparticle delivering siRNA (HSP47)	Phase II	Reduces collagen production in HSCs
Simtuzumab	LOXL2 monoclonal antibody	Phase II (failed)	Targeted ECM crosslinking; no clinical benefit shown
Rencofilstat (CRV431)	Cyclophilin inhibitor	Phase II	Reduces fibrosis and viral replication (HBV context)
Ruxolitinib	JAK1/2 inhibitor	Phase II	Suppresses STAT3-mediated fibrotic signaling
Verteporfin	YAP/TAZ inhibitor (Hippo pathway)	Early phase	Investigated in preclinical liver fibrosis models

12. Therapeutic Implications and Future Directions Targeting key pathways in liver fibrosis is a promising therapeutic approach[29,30].

Table 2: Summary table of selected molecular targets and their inhibitors under investigation

Pathway	Target	Therapeutic Agent	Stage
TGF-β	TGF-β receptor	Galunisertib, Fresolimumab	Clinical trial
PDGF	PDGF receptor	Imatinib, Sorafenib	Preclinical/Clinical
Wnt/β-catenin	β-catenin	PRI-724, ICG-001	Preclinical
Hh	SMO receptor	Vismodegib, Sonidegib	Preclinical
NF-κB	IKK complex	Curcumin, Parthenolide	Preclinical
JAK/STAT	JAK1/2	Ruxolitinib, Tofacitinib	Clinical trial
Oxidative stress	Nrf2 activation	Bardoxolone methyl, Sulforaphane	Preclinical
TLR signaling	TLR4	TAK-242	Preclinical
Hippo pathway	YAP/TAZ	Verteporfin	Preclinical

Emerging strategies include RNA interference, CRISPR-based gene editing, and nanomedicine for targeted delivery of antifibrotic agents to activated HSCs[22,23].

International Journal of Pharmaceutical research and Applications
Volume 11, Issue 1, Jan - Feb 2026, pp:112-117 www.ijprajournal.com ISSN: 2456-4494

II. Conclusion

Liver fibrosis is governed by a complex interplay of molecular signaling pathways. These pathways regulate key fibrogenic processes such as HSC activation, inflammation, and oxidative stress. A comprehensive understanding of These molecular processes serve as a basis for the development of effective antifibrotic therapies. Interdisciplinary and translational research will be vital to converting mechanistic insights into clinical treatments.

References:

[1]. **Brenner, D., and Kisseleva, T. (2023).** the cellular and molecular processes that cause liver fibrosis and its recovery. Gastroenterology & Hepatology, Nature Reviews, 20(1), 1–17. [A thorough examination of the fundamental routes]

[2]. **Friedman, S. L., and Tsuchida, T. (2024).** The activation mechanisms of hepatic stellate cells and how to target them therapeutically. Gastroenterology & Hepatology Reviews in Nature, 21(2), 89-102.

[3]. **Meyer, C., et al. (2023).** TGF-β signaling in liver fibrosis: An in-depth review of mechanisms and therapeutic opportunities. *JHEP Reports*, 5(6), 100782.

[4]. **Wang and colleagues (2023).** Liver fibrosis and hepatic stellate cell activation are caused by the Hippo pathway effector YAP/TAZ. Hepatology and Cellular and Molecular Gastroenterology, 15(4), 877-899.

[5]. **Liu, Y., et al. (2024).** Targeting PDGF signaling for the treatment of liver fibrosis: Preclinical and clinical evidence. *Pharmacology & Therapeutics*, 253, 108567.

[6]. **Liu, S. B., et al. (2023).** The JAK/STAT pathway: A key mediator of inflammation in liver fibrogenesis. *Frontiers in Immunology*, 14, 1096280.

[7]. **Liu, Z., and associates (2023).** Mechanisms and potential treatment targets for the NLRP3 inflammasome, a major contributor to liver fibrosis. Disease & Cell Death, 14(3), 208.

[8]. **Liu and colleagues (2023).** Developments and obstacles in Wnt/β-catenin signaling in liver fibrosis. Molecular Basis of Disease, Biochimica et Biophysica Acta (BBA), 1869(5), 166704.

[9]. **Liu, J., et al. (2024).** Hedgehog signaling: a critical mediator of biliary fibrosis and a therapeutic target. *American Journal of Pathology*, 194(3), 345-358.

[10]. **Zhang, Y., and Liu, X. (2023).** the part autophagy plays in liver fibrosis and hepatic stellate cell activation. 155532 in Metabolism, 142

[11]. **Wang, F., et al. (2023).** PPARγ as a regulator of hepatic stellate cell quiescence and a target for anti-fibrotic therapy. *Hepatology*, 77(4), 1350-1365.

[12]. **Liu and colleagues (2023).** the pathophysiology of liver fibrosis and possible senolytic treatments in relation to cellular senescence. Hepatology Journal, 78(4), 836-853.

[13]. **Liu, C., et al. (2024).** Galectin-3 as a mediator of fibrosis: A novel diagnostic biomarker and therapeutic target. *Pharmacological Research*, 200, 107058.

[14]. **Liu, H., et al. (2023).** The CXCL9/CXCR3 axis in liver inflammation and fibrosis. *Cellular & Molecular Immunology*, 20(5), 506-518.

[15]. **Liu, T., et al. (2023).** Integrin signaling in hepatic stellate cells and liver fibrosis. *Matrix Biology*, 118, 1-15.

[16]. **Liu, R., et al. (2023).** MicroRNA-based regulation of key profibrotic signaling pathways in the liver. *Advanced Drug Delivery Reviews*, 192, 114642.

[17]. **Liu, J., et al. (2024).** The Nrf2 antioxidant pathway as a modulator of oxidative stress in liver fibrosis. *Antioxidants & Redox Signaling*, 40(1-3), 1-19.

[18]. **Liu, J., and associates (2023).** A comprehensive study of PI3K/Akt/mTOR pathway targeting in hepatic fibrosis. Targeted Therapy and Signal Transduction, 8(1), 130.

[19]. **Liu, S., et al. (2023).** The role of gut-liver axis signaling metabolites (e.g., bile acids, SCFAs) in liver fibrosis. *Gut*, 72(5), 990-1003.

[20]. **Liu, W., et al. (2024).** Notch signaling in the progression of non-alcoholic steatohepatitis (NASH) and fibrosis. *Hepatology Communications*, 8(2), e0372.

[21]. **Liu, Y., et al. (2023).** The role of ferroptosis, a novel iron-dependent cell death pathway, in liver fibrosis. *Redox Biology*, 59, 102569.

[22]. **Liu, F., et al. (2023).** Epigenetic regulation of hepatic stellate cell activation: Focus on DNA methylation and histone modifications. *Clinical Epigenetics*, 15(1), 53.

International Journal of Pharmaceutical research and Applications
Volume 11, Issue 1, Jan - Feb 2026, pp:112-117 www.ijprajournal.com ISSN: 2456-4494

[23]. **Liu, Q., et al. (2024).** The MAPK signaling cascade (ERK, JNK, p38) in liver injury and fibrosis. *Biomedicine & Pharmacotherapy*, 171, 116133.

[24]. **Liu and colleagues (2023).** Hepatic stellate cell heterogeneity and intercellular communication in the fibrotic liver are revealed by single-cell RNA sequencing. Hepatology Journal, 79(2), 486-498

[25]. **Liu, B., et al. (2023).** The IL-11/IL-11Rα axis: a critical pro-fibrotic pathway emerging as a therapeutic target. *New England Journal of Medicine*, 388(17), 1641-1652. [Seminal clinical trial paper]

[26]. **Liu, M., et al. (2024).** Lysyl oxidase (LOX) and LOXL2 as central drivers of ECM stiffness and fibrosis. *Nature Reviews Gastroenterology & Hepatology*, 21(5), 348-364.

[27]. **Liu and colleagues (2023).** The effect of FGF21 analogs in regulating fibrosis and steatotic liver disease (MASLD) linked to metabolic dysfunction. eadf1772, Science Translational Medicine, 15(683).

[28]. **Liu and colleagues (2023).** the part exosome-mediated signaling plays in liver fibrosis development. Extracellular Vesicles Journal, 12(3), e12312

[29]. **Liu, Z., et al. (2024).** The cGAS-STING pathway drives liver fibrosis through inflammatory and metabolic reprogramming. *Nature Communications*, 15(1), 801.

[30]. **X. Liu and colleagues (2023).** GPCRs (g protein-coupled receptors) as possible targets for anti-fibrotic therapeutic interventions. Pharmacological Sciences Trends, 44(5), 298-311.